What differs between the tumour and healthy cells is density, not identity.
What differs between the tumour and healthy cells is density, not identity.
Read more: www.onclive.com/view/pertuzu...
Read more: www.onclive.com/view/pertuzu...
https://www.stocktitan.net/news/OLMA/olema-oncology-presents-preclinical-data-on-selective-kat6a-b309dkg5r3nk.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/OLMA/olema-oncology-presents-preclinical-data-on-selective-kat6a-b309dkg5r3nk.html?utm_source=stocktitan-bluesky&utm_medium=social
🔗 Source: https://pubmed.ncbi.nlm.nih.gov/43035167/
🔗 Source: https://pubmed.ncbi.nlm.nih.gov/43035167/
Full video ➡️: www.onclive.com/view/dr-trai...
Full video ➡️: www.onclive.com/view/dr-trai...
www.fda.gov/drugs/cancer...
www.fda.gov/drugs/cancer...
晚期HER2弱陽性治療拼圖 醫:45%乳癌苦盼健保接軌
(中央社記者陳婕翎台北15日電)健保署近年開放新藥給付於荷爾蒙陰性的HER2弱陽性乳癌晚期患者;醫師指出,占總體乳癌約45%的荷爾蒙陽性HER2弱陽性病友,仍苦等健保接軌,呼籲儘速補齊晚期乳癌治療拼圖。
https://www.cna.com.tw/news/ahel/202611150109.aspx
#新聞
晚期HER2弱陽性治療拼圖 醫:45%乳癌苦盼健保接軌
(中央社記者陳婕翎台北15日電)健保署近年開放新藥給付於荷爾蒙陰性的HER2弱陽性乳癌晚期患者;醫師指出,占總體乳癌約45%的荷爾蒙陽性HER2弱陽性病友,仍苦等健保接軌,呼籲儘速補齊晚期乳癌治療拼圖。
https://www.cna.com.tw/news/ahel/202611150109.aspx
#新聞
Lung cancer is the leading cause of cancer death in Japan. This approval is an important step forward for people facing HER2-driven lung cancer.
go.boehringer.com/E3zcB
Lung cancer is the leading cause of cancer death in Japan. This approval is an important step forward for people facing HER2-driven lung cancer.
go.boehringer.com/E3zcB
Read more: www.foundationmedicine.com/press-releas...
Read more: www.foundationmedicine.com/press-releas...